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bjectives This study aimed to determine the success, complications, and survival of patients after
alloon aortic valvuloplasty (BAV).
ackground The introduction of transcatheter aortic valve implantation (TAVI) BAV has led to a re-
ival in the treatment of patients with severe aortic stenosis.
ethods A cohort of 262 patients with severe aortic stenosis underwent 301 BAV procedures. Of
hese, 39 (14.8%) patients had 2 BAV procedures. Clinical, hemodynamic, and follow-up mortality
ata were collected.
esults The cohort mean age was 81.7  9.8 years, and the mean Society of Thoracic Surgeons
nd logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) was 13.3  6.7 and
5.6  21.6, respectively. BAV was performed as a bridge to TAVI or to surgical aortic valve replace-
ent in 28 patients (10.6%) and for symptom relief in 234 (89.4%). The mean aortic valve area (AVA)
ncreased from 0.58  0.3 cm2 to 0.96  0.3 cm2 (p  0.001). Of these, 111 (45.0%) had ﬁnal AVA
1 cm2, and in 195 patients (79%), AVA increased by 40%. De novo BAV resulted in a higher
ean increase in AVA 0.41  0.24 cm2 versus 0.28  0.24 cm2 in redo BAV (p  0.003). Serious ad-
erse events occurred in 47 patients (15.6%), intraprocedural death in 5 (1.6%), stroke in 6 (1.99%),
oronary occlusion in 2 (0.66%), severe aortic regurgitation in 4 (1.3%), resuscitation/cardioversion in
(1.6%), tamponade in 1 (0.33%), and permanent pacemaker in 3 (0.99%). A vascular complication
ccurred in 21 patients (6.9%); 34 (11.3%) had a post-procedure rise in creatinine 50%; and 3
0.99%) required hemodialysis. During median follow-up of 181 days, the mortality rate was 50%
n  131). The mortality rate in the group with ﬁnal AVA 1 cm2 was signiﬁcantly lower than in the
roup with ﬁnal AVA of 1 cm2 (36.4% vs. 57.9%, p  0.001). Final AVA was associated with lower
ortality (hazard ratio: 0.46, p  0.03). BAV as a bridge to TAVI or surgical aortic valve replacement
ad a better outcome compared with BAV alone: mortality rate 7 (25%) versus 124 (52.9%), respec-
ively (p  0.0001).
onclusions Long-term survival is poor after BAV alone. BAV as a bridge to percutaneous or surgi-
al aortic valve replacement is feasible, safe, and associated with better outcome than BAV
lone. (J Am Coll Cardiol Intv 2010;3:1150–6) © 2010 by the American College of Cardiology
oundation
rom the Division of Cardiology, Washington Hospital Center, Washington, DC. The authors have reported that they have no
elationships to disclose.anuscript received April 26, 2010; revised manuscript received June 21, 2010, accepted August 5, 2010.
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1151ritical aortic stenosis (AS) affects an estimated 4.6% of
ndividuals over 75 years of age (1). Aortic valve replace-
ent surgery is the treatment of choice for symptomatic
alcific AS. The prognosis is poor for patients with severe
ymptomatic AS without surgical treatment, with an aver-
ge survival of only 1 to 3 years after symptom onset (2).
espite these facts, many symptomatic patients do not
ndergo operation due to high operative risk owing to their
ultiple comorbidities. In the Euro Heart Survey (3),
1.8% of patients received no surgical valve replacement
espite indication. Transcatheter aortic valve implantation
TAVI) is under study as an alternative treatment modality
or high-risk, severe, symptomatic AS.
Many patients with severe, symptomatic AS who are
creened for TAVI trials and are found not eligible based on
trict inclusion/exclusion criteria are referred for balloon
ortic valvuloplasty (BAV). BAV, introduced by Cribier et
l. (4) in 1986, is a useful, palliative treatment for symp-
omatic relief and can be used as a bridge to more definitive
urgical replacement or TAVI in hemodynamically unstable
atients (5). The aim of this study was to determine the
uccess, complication rates, and survival of patients after
AV and to define the clinical, invasive, and echocardio-
raphic variables related to long-term outcome after this
rocedure.
ethods
atient population. From January 2000 to December 2009,
he data from 301 BAV procedures in 262 consecutive
atients with severe symptomatic AS were prospectively
ntered into a dedicated database. The cohort consisted of
1 patients (11.8%) from the pre-TAVI era, 29 (11.0%)
ere included in the BAV arm of the TAVI trial, and 28
10.6%) had BAV as a bridge for surgical valve replacement
r TAVI. Of the remaining 174 patients excluded from the
AVI trial, 49 (28.1%) had1 exclusion criteria. The main
xclusion criteria were peripheral vascular or aorta disease in
0 patients (17.9%), significant coronary artery disease
equiring revascularization in 37 (16.5%), renal failure in 23
10.3%), ejection fraction 20% in 22 (9.8%), low Society
f Thoracic Surgeons (STS) score10% in 16 (7.1%), other
ignificant valvular disease in 15 (6.7%), aortic valve area
0.8 cm2 in 13 (5.8%), and others (e.g., neurological
isease, unstable, refuse, bleeding diathesis, large-size an-
ulus) in 57 (25.5%). All patients had severe, symptomatic
S confirmed by transthoracic echocardiography and he-
odynamic evaluation. Patients were referred for BAV for
alliation of heart failure symptoms, treatment of cardio-
enic shock, and, as a bridge for TAVI, surgical aortic valve
eplacement or noncardiac surgery. The STS score and the
ogistic EuroSCORE (European System for Cardiac Oper-
tive Risk Evaluation) were calculated for all patients.
n-hospital clinical events were determined from the review af medical records. Follow-up was obtained by trained
edical personnel using direct telephone interviews and
eview of medical records both in-hospital and during
ollow-up outpatient physician visits.
chocardiographic data. Echocardiography was performed
ith commercially available ultrasound systems. All patients
nderwent a comprehensive examination that included
-mode, 2-dimensional echocardiography, and conven-
ional and color Doppler by an experienced echocardiogra-
her before and after BAV. Multiple transducer positions
ere used to record peak aortic jet velocities, and aortic valve
rea (AVA) was calculated with the continuity equation.
rocedures. Diagnostic right and left heart catheterization
as performed on all patients. Heparin was administrated in
ll patients 10 to 70 U/kg after 9- to 13-F sheath insertion
n the femoral artery. BAV was performed according to
tandard techniques via the retrograde femoral approach in
ll patients except 1. In that individual, axillary artery access
as employed because of severe peripheral vascular disease.
qualization of pressures was documented before entering
he left ventricle. The gradient was confirmed with pullback
radient measurements. Peak
nd mean gradients were mea-
ured, and AVA was calculated
ith the Gorlin formula.
The sinotubular junction is
he site prone to rupture during
BAV procedure. We analyzed
he minimal diameter of the si-
otubular junction by aortogram
n the left anterior oblique with a
arker pigtail and by echocardi-
graphy. The chosen balloon
ize was 3 to 5 mm under this measurement. To stabilize the
alloon position across the valve, the heart was paced at a
igh rate (180 to 200 beats/min) until the blood pressure fell
o50 mm Hg before inflation. Pacing was continued until
he balloon was fully deflated. Additional BAV procedures
ere performed subsequently in cases in which the mean
radients did not decrease significantly (30% to 40%), and
larger balloon was employed in selected cases in which the
nitial balloon size failed to significantly decrease gradients
30% to 40%). At the end of the procedure, measurements
f cardiac output and pressure gradients and calculations
ere repeated. After BAV, an aortogram was performed to
ssess aortic regurgitation. Arterial puncture sites were
losed with closure devices (6-F Perclose [Abbott Labora-
ories, Abbott Park, Illinois] or 12-F Prostar [Abbott] or
-F Angio-Seal [St. Jude Medical, St. Paul, Minnesota]). If
he device failed, manual compression was applied. Serious
dverse events were defined as intraprocedural death, stroke,
oronary occlusion or dissection, moderate-to-severe aortic
egurgitation, profound hypotension requiring resuscitation
Abbreviations
and Acronyms
AS  aortic stenosis
AVA  aortic valve area
BAV  balloon aortic
valvuloplasty
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantationnd intubation or cardioversion, tamponade, permanent
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1152acemaker requirement, and vascular complication requir-
ng intervention.
tatistical analysis. Continuous variables are presented as
ean  SD and categorical variables are presented as
ercentages. Days of follow-up are presented as median
25th, 75th percentiles). Differences between continuous
ariables were assessed by Student t test. Paired tests were
nalyzed by paired Student t test. Categorical variables were
ompared using the chi-square test or Fisher exact test as
ndicated. Significance was set at p  0.05. Cumulative
urvival curves were constructed using the Kaplan-Meier
ethod and compared by the log-rank test. The Cox
roportional hazard regression method was used to examine
he univariable association of clinical, catheterization, and
chocardiographic variables with event-free survival. Multi-
ariable associations within these same groups were also
valuated. All continuous variables were measured in their
riginal scale.
esults
AV procedures. The cohort included 262 patients who
nderwent 301 BAV procedures. Among these patients, 29
nderwent 2 BAV, 8 underwent 3 BAV, and 2 underwent
BAV procedures. Of the 301 BAV procedures, 114
37.8%) were done with concomitant diagnostic coronary
ngiography and 52 (17.2%) were done with concomitant
ercutaneous coronary intervention. After the introduction
f TAVI, there was a steep increase in the number of
rocedures performed each year; most of the patients were
creened for the trial but were not eligible based on the
nclusion/exclusion criteria (Fig. 1). Indications for the
AV procedures included symptom relief in 210 (80.2%),
ardiogenic shock in 24 (9.1%), bridge for TAVI in 13
4.9%), and bridge for surgical aortic valve replacement
n 15 (5.7%) (Fig. 2).
Figure 1. BAV per Year From 2000 to 2009
The number of balloon aortic valvuloplasty (BAV) procedures per year from
2000 to 2009.Baseline characteristics are displayed in Table 1. The
atients were at high risk with a mean age of 81.7  9.8
ears and mean STS and a logistic EuroSCORE of 13.3 
.7 and 45.6  21.6, respectively. Laboratory values, echo-
ardiographic data, and right heart catheterization data
efore and after BAV are presented in Table 2.
VA. The mean AVA by invasive hemodynamic data in-
reased from 0.58 0.3 cm2 to 0.96 0.3 cm2 (p 0.001).
Figure 2. Indication for BAV
*Or evaluation of reversibility of severe left ventricular dysfunction/evalua-
tion of reversibility of severe mitral regurgitation and severe pulmonary
hypertension. AVR  aortic valve replacement; BAV  balloon aortic valvu-
loplasty; TAVI  transcatheter aortic valve implantation.
Table 1. Baseline Characteristics
Variable BAV (n  262)
Age, yrs 81.7 9.8
Female sex 145 (55.3%)
STS score, % 13.3 6.7
Standard EuroSCORE 13.8 3.1
Logistic EuroSCORE 45.6 21.6
Cardiogenic shock 24 (9.1%)
NYHA functional class IV 149 (56.8%)
NYHA functional class II or III 113 (43.1%)
Body mass index, kg/m2 26.9 7.2
Diabetes 93 (35.5%)
Hypertension 227 (86.6%)
Hyperlipidemia 193 (73.6%)
Coronary artery disease 168 (64.1%)
Chronic obstructive pulmonary disease 71 (27.1%)
Renal failure, CrCl 60 ml/min 122 (46.5%)
Prior CVA/TIA 53 (20.2%)
Atrial ﬁbrillation 108 (41.2%)
Peripheral vascular disease 97 (37%)
Prior coronary artery bypass grafting 81 (30.9%)
Prior percutaneous coronary intervention 44 (16.8%)
Values are mean SD or n (%).
BAV  balloon aortic valvuloplasty; CrCl  creatinine clearance; CVA  cerebrovascular
accident; EuroSCORE  European System for Cardiac Operative Risk Evaluation; NYHA  NewYork Heart Association; STS Society of Thoracic Surgeons; TIA transient ischemic attack.
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1153f these, 111 (45.0%) had final AVA 1 cm2. In 195
atients (79.0%), the AVA increased by 40%. After the
nitial BAV, the mean increase in valve area was 0.41 0.24
m2 higher compared with the group who had redo BAV,
ith a mean increase in AVA of only 0.28 0.24 cm2 (p 
.003).
omplications. The median hospital duration was 4 days
interquartile range [IQR]: 2.8 days). Fifty-three patients
17.6%) required blood transfusion. A rise in creatinine
50% was observed in 34 patients (11.3%). Three (0.99%)
equired hemodialysis. The mean rise in troponin was 1.1
.5 ng/dl and in creatine kinase-myocardial band was
.94  5.0 U/l. Serious adverse events occurred in 47
atients (15.6%) (Table 3).
ortality. During a median follow-up of 181 days (IQR:
6, 436 days) the mortality rate was 50% (n  131). The
edian time from BAV to death was 95.5 days (IQR: 24.5,
52.75 days) (Fig. 3). Final valve area was associated with
ower mortality (hazard ratio [HR]: 0.46, 95% confidence
nterval [CI]: 0.22 to 0.95, p  0.03). However, the
bsolute increase in AVA and the percentage increase in
alve area were not associated with lower mortality (HR:
.48, 95% CI: 0.19 to 1.22, p  0.12) and (HR: 1.00, 95%
I: 0.99 to 1.01, p  0.22), respectively. The mortality of
he group with final AVA 1 cm2 was significantly lower
han the group with final AVA of1 cm2 (36.4% vs. 57.9%,
 0.001); however, there was no significant difference
etween the 2 groups with increased valve areas of40% vs.
40% (49.7% vs. 50.9%, respectively, p  0.7). Balloon
Table 2. Laboratory Values, Echocardiographic Data,
Before and After BAV
B
Laboratory values
Hematocrit, %
Hemoglobin level, mg %
Creatinine, mg %
cTnI, ng/ml
Echocardiography parameters
Ejection fraction, %
AVA, cm2
Vmax, m/s
Mean gradients across aortic valve, mm Hg
Max gradients across aortic valve, mm Hg
Pulmonary artery systolic pressure, mm Hg
Right heart hemodynamic parameters
AVA, cm2
Mean gradients across aortic valve, mm Hg
Pulmonary artery systolic pressure, mm Hg
Cardiac output, l/min
AVA aortic valve area; cTnI cardiac troponin I; Vmaxmaximumortic valvuloplasty as a bridge to TAVI or surgical aortic aalve replacement, when compared with BAV alone, had a
etter outcome: mortality rate 7 (25%) versus 124 (52.9%),
espectively (p  0.0001) (Fig. 4).
Clinical and laboratory values, echocardiographic data,
ight heart catheterization data, and procedural factors
ssociated with mortality are presented in Table 4. After
ultivariable adjustment, the strongest predictors for mor-
ality were New York Heart Association functional class IV
HR: 4.91, 95% CI: 1.88 to 12.8, p  0.01), baseline renal
ailure (HR: 2.23, 95% CI: 1.46 to 2.98, p  0.01),
ulmonary systolic pressure (HR: 1.03, 95% CI: 1.01 to
.06, p  0.01), hematocrit drop (HR: 1.16, 95% CI: 1.04
o 1.3, p 0.01). Balloon aortic valvuloplasty as a bridge for
efinitive therapy was independently associated with lower
ortality failure (HR: 0.10, 95% CI: 0.01 to 0.93, p 0.04).
iscussion
ur study confirms an exceedingly poor prognosis for
atients with symptomatic severe AS undergoing BAV–
ith mortality rates of up to 50% at a median follow-up
eriod of 6 months. This observation is in accordance with
ates previously reported. Liberman et al. (6) found survival
ates of 52%, 31%, and 18% at 1, 2, and 3 years after BAV,
espectively. Otto et al. (7) reported 55% survival at 1 year,
5% at 2 years, and 23% at 3 years. Initial enthusiasm in the
ate 1980s for BAV in adults with calcific AS was subse-
uently tempered by studies demonstrating that although
here was initial symptomatic improvement (8), it was
ight Heart Catheterization Data
BAV
n  286) After (n  286) p Value
 4.9 29.7 5.0 0.001
 1.7 9.6 1.7 0.001
 1.2 1.8 1.8 0.001
 7.2 2.3 9.5 0.002
 18.4 47.0 18.0 0.02
 0.15 0.87 0.19 0.001
 0.60 3.5 0.6 0.001
 13.9 31.9 11.8 0.001
 21.9 52.6 18.4 0.001
 18.6 48.9 17.3 0.03
 0.3 0.96 0.3 0.001
 19.7 21.4 12.4 0.001
 16.8 50.6 18.0 0.01
 1.1 4.1 1.2 0.003
; other abbreviations as in Table 1.and R
efore (
35.4
11.4
1.5
0.93
45.4
0.68
4.05
42.0
68.1
53.6
0.58
46.3
54.9
3.8ssociated with high complication and recurrence rates (9),
a
p
o
c
f
t
B
t
i
w
p
0
w
b
6
b
o
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 1 , 2 0 1 0
N O V E M B E R 2 0 1 0 : 1 1 5 0 – 6
Ben-Dor et al.
Balloon Aortic Valvuloplasty
1154nd little impact on long-term survival, therefore, the
rocedure was rarely undertaken (7). With the introduction
f TAVI, there has been a resurgence in BAV. At our
enter, the number of BAV procedures performed increased
rom 4.4 annually to 88.6 after the introduction of TAVI.
Table 3. Serious Adverse Events in 262 Patients Undergoing
301 BAV Procedures
Serious Adverse Event 47 (15.6%)
Intraprocedural death 5 (1.6%)
Stroke 6 (1.99%)
Coronary occlusion/dissection 2 (0.66%)
Moderate-severe aortic regurgitation 4 (1.3%)
Profound hypotension requiring resuscitation and
intubation or cardioversion
5 (1.6%)
Tamponade 1 (0.3%)
Permanent pacemaker 3 (0.99%)
Serious vascular complication requiring intervention 21 (6.9%)
Perforation 5 (1.6%)
Ischemic leg 8 (2.6%)
Pseudoaneurysm 6 (1.99%)
Arterial-venous ﬁstula 2 (0.66%)
BAV balloon aortic valvuloplasty.
Table 4. Clinical and Laboratory Values, Echocardiographic Data,
Right Heart Catheterization Data, and Procedural Factors Associated
With Mortality
Univariable Cox Analysis
Hazard
Ratio 95% CI p Value
Prior to the procedure
Male sex 1.43 1.01 to 2.01 0.04
Cardiogenic shock 2.5 1.50 to 4.10 0.001
NYHA functional class IV 2.97 1.90 to 4.50 0.001
Renal Failure 2.09 1.46 to 2.98 0.001
Sodium level 0.95 0.90 to 0.99 0.01
Septal thickness 0.15 0.005 to 0.43 0.001
Final AVA 0.46 0.22 to 0.95 0.03
Aortic systolic pressure 0.99 0.98 to1.00 0.03
BAV as a bridge to percutaneous or
surgical aortic valve replacement
0.35 0.16 to 0.74 0.006
Post-procedure variables
Delta drop in hematocrit level 1.1 1.06 to 1.14 0.001
Delta rise in creatinine level 1.42 1.22 to 1.67 0.001
Delta rise in troponin level 1.02 1.00 to 1.03 0.04
Multivariate Cox analysis
Renal failure 2.7 1.20 to 5.70 0.009
NYHA functional class IV 5.3 1.60 to 17.5 0.006
Pulmonary pressure 1.03 1.01 to 1.06 0.01
Delta drop in hematocrit level 1.13 1.02 to 1.25 0.01
BAV as a bridge to percutaneous or
surgical aortic valve replacement
0.1 0.01 to 0.93 0.04
The variables included are listed in Tables 1 and 2.CI confidence interval; other abbreviations as in Tables 1 and 2.Multiple modifications have been made in the BAV
echnique over the years. Rapid ventricular pacing during
AV enables precise and stable balloon positioning. This
echnique was reported recently to result in a lesser increase
n AVA when compared with performing the procedure
ithout rapid ventricular pacing (0.24  0.2 vs. 0.38  0.3,
 0.01) (10). The mean increase in AVA in our study was
.4  0.25 cm2 when 90% of the procedures were done
ith rapid ventricular pacing. Vascular complications have
een lowered from the previously reported 13.5% (11) to
.9%. This improvement may be attributed to the newer
alloon catheter that allows the use of a 10-F sheath instead
f a 13-F sheath, as well as the availability of closure devices.
oreover, most of our patients had an assessment of the
Figure 3. Kaplan-Meier Survival Curves of Patients Undergoing BAV
Kaplan-Meier survival curves of patients undergoing BAV. Red solid line 
ﬁnal AVA 1 cm2; black dashed line  ﬁnal aortic valve area 1 cm2).
AVA  aortic valve area; other abbreviations as in Figures 1 and 2.
Figure 4. Kaplan-Meier Survival Curves of Patients Undergoing BAV Only
Versus BAV as a Bridge to TAVI or Surgical AVR
Kaplan-Meier survival curves of patients undergoing BAV only (red line) or
BAV as a bridge to TAVI or surgical AVR (black line). Abbreviations as in
Figures 1, 2 and 3.
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1155eripheral vascular tree by contrast computer tomography as
part of screening for TAVI, thereby allowing us to choose
he better side for a safer vascular approach. These changes
nd others have led to overall lower complication rates. In
ur series, we experienced a 16.2% severe complication rate
ompared with 31% reported previously (8). The duration of
ospitalization after the procedure was shorter, with a mean
ength of stay of 4 days compared with the previously
eported 7.6 days (8).
inal AVA. The overall change in AVA in our study from
.58  0.3 cm2 to 0.96  0.3 cm2 is higher than was
reviously reported in other large series (n  100). In the
ational Heart Lung and Blood Institute Balloon Valvulo-
lasty Registry, the AVA increased from 0.5 to 0.8 cm2 (7).
n the Mansfield registry, the AVA increased from 0.5 to
.82 cm2 (12), whereas Liberman et al. (6) reported an
ncrease in AVA from 0.5 to 0.7 cm2. Agarwal et al. (11)
eported an increase from 0.61 to 1.2 cm2. Patients sub-
ected to redo BAV had significantly lower AVA post-
rocedure when compared with patients with de novo BAV
0.28  0.24 cm2 vs. 0.41  0.24 cm2, p  0.001). These
ata are in concordance with Kuntz et al. (13), who reported
lower post-valvuloplasty AVA in patients after repeat
AV compared with the first procedure. Feldman et al. (14)
ound in a series of 85 patients less improvement in AVA
fter the second BAV compared with the first BAV (0.2 
.13 cm2 vs. 0.45  0.17 cm2, p  0.01).
Restenosis is evident as early as a few days after BAV.
oung scar tissue gradually fills up splits between commis-
ures, small tears or lacerations in the collagenous valve
troma, and fractures in calcifications (15,16). Histologic
hanges in restenosed valves differ from those seen initially
n calcific AS, with granulation tissue, fibrosis, and ossifi-
ation being present (13). This process may lead to limited
esults of second dilations.
redictors of mortality. Predictors of mortality in patients
ndergoing BAV have been previously reported (7,17). In
he largest series of patients undergoing BAV, multivariate
nalysis demonstrated baseline functional status, baseline
ardiac output, renal function, cachexia, female sex, left
entricular systolic function, and mitral regurgitation as
ndependent predictors of mortality (7). The present study
etected New York Heart Association functional class IV as
predictor for mortality. This is not surprising because
unctional status is a well-known determinant of prognosis
n patients with severe AS treated medically (18,19). Renal
nsufficiency was an independent predictor for mortality; in
revious studies (20–22), renal failure was reported to be
ssociated with worse outcomes in high-risk patients un-
ergoing aortic valve replacement surgery. High pulmonary
rtery pressure in our cohort and in other series was
ssociated with poor outcome as well (23). As opposed to
ther cardiovascular disease, we found women to have
igher survival rates than men (Table 4).AV as a bridge to TAVI/surgical aortic valve replacement. In
ur study, the outcome of patients who had the BAV
rocedure as a bridge to TAVI or surgical aortic valve
eplacement was much better when compared with patients
ho had the BAV procedure only. Kuntz et al. (24) reported
etter actuarial event-free survival of octogenarians after
urgical aortic valve replacement compared with 205 pa-
ients treated by BAV. Some patients who initially had
AV as an alternative to surgical aortic valve replacement or
AVI because of prohibitive perioperative risks may later
ecome candidates at the time of restenosis (25). Balloon
ortic valvuloplasty should be followed by more definitive
reatment in all suitable cases. Other studies reported
ridging to TAVI with BAV as a feasible and reasonably
afe approach to offer temporary relief in selected high-risk
atients with symptomatic severe AS and a high chance of
eriprocedural complications (26,27).
tudy limitations. This retrospective, observational report
as several limitations. Among them are the long time
eriod, which included change in technique and the lack of
control group. However, this is among the largest series of
atients reported in the literature. The definition of suc-
essful BAV as final AVA 1 cm2 associated with a lower
ortality rate should be viewed with caution due to the lack
f a control group, which was treated medically only. A
rospective, randomized study comparing valvuloplasty to
edical therapy is necessary to define the true potential
urvival benefit from BAV. The high mortality/morbidity
ates in this group of patients may have been influenced by
he number of patients with very severe comorbidities
valuated for the TAVI trial.
onclusions
ong-term survival is dismal after BAV alone. Transcath-
ter or surgical aortic valve replacement should be pursued
ecause BAV as a bridge to transcatheter or surgical aortic
alve replacement is feasible, safe, and associated with better
utcome than BAV alone. This may be especially true in
atients who develop restenosis after the first BAV because
he second BAV is associated with a lesser increase in AVA.
eprint requests and correspondence: Dr. Ron Waksman,
ashington Hospital Center, 110 Irving Street, NW, Suite 4B-1,
ashington, DC 20010. E-mail: ron.waksman@medstar.net.
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